4DMedical (4DX.AX) Stock Price

4DMedical Price

ASX·CLOSED
4.09
​
Market closed

Over the last 12 years 4DMedical grew revenue by 32.0% annually, reaching 7.06 M AUD. For 4DMedical, the net margin of -2,895.1% is down versus -2,332.6% a few years ago. The consensus 12-month price target for 4DMedical is 3.26 AUD, about 20.2% below where the stock trades today. Of 7 analysts, 5 rate the stock a buy — an overall Buy consensus.

4DMedical stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

4DMedical business model & stock analysis

4DMedical Ltd, headquartered in Melbourne, Australia, operates in the Health Care sector, specializing in four-dimensional lung imaging technology. The company commercializes its patented XV Technology, enabling physicians to assess regional airflow and identify respiratory issues earlier through its FDA-cleared XV Lung Ventilation Analysis Software (XV LVA) and CT LVAS. These solutions, delivered via a SaaS model, utilize existing hospital imaging equipment or the company's XV Scanner, with commercial rollout initiated through partnerships like I-MED Radiology Network, serving approximately 250 clinics nationwide.

Frequently asked questions about 4DMedical

Analysts currently set an average price target of 3.47 AUD for the 4DMedical stock (median: 3.26 AUD), implying -15.2 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the 4DMedical stock: 5 recommend buying, 1 holding and 1 selling.

Converted at the current exchange rate, the 4DMedical share trades at 2.53 EUR (4.09 AUD).

The 4DMedical share (4DX.AX) is listed on 2 stock exchanges, including: ASX (4DX.AX).

The revenue of 4DMedical is 7.06 M AUD. This figure is based on current financial data and reflects the company's business performance.

The profit of 4DMedical is -204.44 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of 4DMedical is currently -136.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the 4DMedical stock.

The price-to-sales ratio (P/S) of 4DMedical is currently 3,946.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the 4DMedical stock.

The Eulerpool Quality Score for 4DMedical is 3/10.

The ISIN of 4DMedical is AU0000095416. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of 4DMedical is 4DX.AX. The ticker symbol is used to trade 4DMedical shares on the stock exchange.

Fair ValueTerminal
3.97 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Technology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Australia
Currency
AUD
Initial public offering
Aug 7, 2020
ISIN
AU0000095416
Cusip
Q3927K101
Market capitalization
2.33 B AUDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-880.29
P/Ee 2028
-5,355.88
P/Ee 2029
92.12
P/Se
1,251.71
EV/EBIT
—
P/B Ratio
13.70
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-117.91 %
Last updated Oct 18, 2026, 5:39 AM

4DMedical Peer Group

4DMedical Ticker

ASX · 4DX.AXOTC · FDMDF

4DMedical FIGI

4DX:AU · BBG00VSFDKK64DX:AT · BBG00VSFDKL54DX:AH · BBG00VSFDKQ0FDMDF:US · BBG00YFSCTR1FDMDF:PQ · BBG00YFSCV69FDMDF:UV · BBG00YFSCV78

All fundamentals and in-depth analysis of 4DMedical

Our stock analysis for 4DMedical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 4DMedical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.